Enhanced treatment for MAC infection in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This trial compares a new, enhanced treatment approach with the standard care for people living with HIV who have a serious bacterial infection called disseminated MAC (Mycobacterium avium complex). The goal is to see if the enhanced strategy works better. You might benefit from participating if you have this infection and are about to start treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have confirmed HIV infection.
- You must have a confirmed disseminated MAC infection (bacteria found in blood, bone marrow, or other sterile body sites) with symptoms like fever or weight loss.
- You must be about to start or have just started (within the last 14 days) the standard antibiotics for this infection.
- You cannot have already been treated for more than 14 days for this infection, or have known resistance to certain antibiotics (macrolides).
- You cannot have severe heart rhythm problems, low potassium/magnesium levels that are not corrected, or be taking medicines that affect heart rhythm.
- You cannot have severe liver or kidney disease, be pregnant or breastfeeding, or have an allergy to the study antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
This trial studies how much medicine is needed (based on lab results) to treat MAC lung disease, an infection in the lungs. If you already have MAC and are receiving the recommended core antibiotics, your care may help researchers link treatment details to lab measurements.
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
This trial tests whether inhaled hypertonic saline can improve symptoms and lung health in people with a specific lung infection called MAC. It targets adults with confirmed MAC infection and bronchiectasis who are not already on certain MAC medications.
Hear when a new Opportunistic Infections, HIV Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.